Orleans Capital Management Corp LA reduced its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 2.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,861 shares of the company’s stock after selling 180 shares during the period. Orleans Capital Management Corp LA’s holdings in Zoetis were worth $1,363,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Webster Bank N. A. boosted its position in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares in the last quarter. Quarry LP boosted its holdings in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares in the last quarter. Neo Ivy Capital Management acquired a new position in Zoetis in the fourth quarter valued at approximately $40,000. LRI Investments LLC purchased a new position in Zoetis in the first quarter valued at approximately $43,000. Finally, Hazlett Burt & Watson Inc. raised its holdings in Zoetis by 60.7% during the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after purchasing an additional 102 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.
Zoetis Price Performance
Shares of ZTS opened at $195.38 on Tuesday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The firm has a 50-day simple moving average of $186.33 and a 200-day simple moving average of $174.93. The company has a market capitalization of $88.52 billion, a price-to-earnings ratio of 37.65, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on ZTS. Stifel Nicolaus upped their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $220.38.
View Our Latest Stock Analysis on ZTS
About Zoetis
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- How to Evaluate a Stock Before BuyingÂ
- Instacart Is Revolutionizing Groceries: Why It’s Time to Invest
- Using the MarketBeat Dividend Yield Calculator
- DraftKings Is the Real MVP of the 2025 NFL Football Season
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- TJX Stock: A Buying Opportunity Before the Holiday Rush
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.